Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: Subgroup analysis of two phase 1 studies.

被引：10
|
作者：
Bando, Hideaki
Kinoshita, Ichiro
Modi, Shanu
Tsurutani, Junji
Bang, Yung-Jue
Iwata, Hiroji
Sato, Yuta
Nakatani, Shunsuke
Lee, Caleb C.
Sugihara, Masahiro
Okuda, Yasuyuki
Takahashi, Shunji
机构：
[1] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[2] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Showa Univ, Tokyo, Japan
[5] Seoul Natl Univ, Coll Med, Seoul, South Korea
[6] Daiichi Sankyo Co Ltd, Tokyo, Japan
[7] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[8] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Med Oncol, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.6079
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6079
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma.
    Shitara, Kohei
    Enzinger, Peter C.
    Mohapatra, Avani
    Janjigian, Yelena Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS508 - TPS508
  • [12] Targeted therapy with trastuzumab for epidermal growth factor receptor 2 (HER2)-positive advanced salivary duct carcinoma: A case report
    Gibo, Takahiko
    Sekiguchi, Nodoka
    Gomi, Daisuke
    Noguchi, Takuro
    Fukushima, Toshirou
    Kobayashi, Takashi
    Ozawa, Takesumi
    Yamada, Shin-Ichi
    Koizumi, Tomonobu
    MOLECULAR AND CLINICAL ONCOLOGY, 2019, 11 (02) : 111 - 115
  • [13] A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases
    Andre, F.
    Cortes, J.
    Curigliano, G.
    Modi, S.
    Li, W.
    Park, Y. H.
    Chung, W. -p.
    Kim, S. -b.
    Yamashita, T.
    Pedrini, J. L.
    Im, S. -a.
    Tseng, L. -m.
    Harbeck, N.
    Krop, I.
    Nakatani, S.
    Tecson, K.
    Ashfaque, S.
    Egorov, A.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2024, 35 (12) : 1169 - 1180
  • [14] Rescue Therapy with Trastuzumab Deruxtecan (T-Dxd) in Patients with primary hepatic metastatic Her2 low Breast Cancer with marked Hyperbilirubinemia
    Wolf, M.
    Sili, F.
    Sulejmani, V.
    Schuepferling, A.
    Bomhard, J.
    Huber, M.
    Sigl, S.
    Schnelzer, A.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (06) : E44 - E44
  • [15] Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma
    Takahashi, Hideaki
    Tada, Yuichiro
    Saotome, Takashi
    Akazawa, Kohei
    Ojiri, Hiroya
    Fushimi, Chihiro
    Masubuchi, Tatsuo
    Matsuki, Takashi
    Tani, Kaori
    Osamura, Robert Y.
    Hirai, Hideaki
    Yamada, Shuhei
    Kawakita, Daisuke
    Miura, Kouki
    Kamata, Shin-etsu
    Nagao, Toshitaka
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (02) : 125 - +
  • [16] A meta-analysis of the difference in response to trastuzumab-deruxtecan (T-DXd) based on HER2 immunohistochemistry (IHC) in HER2 low metastatic breast cancer (mBC)
    Kumar, Prashanth Ashok
    Sandhu, Michael
    Sravanthi, Metlapalli Venkata
    Kumar, Vishnu Charan Suresh
    Benjamin, Sam
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [17] The efficacy and safety of trastuzumab deruxtecan (T-DXd) in HER2-expressing solid tumours: a single-arm meta-analysis
    Kou, Liqiu
    Chen, Xiu
    Xie, Xiaolu
    Wen, Qinglian
    Li, Jun
    Li, Yaling
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (08) : 722 - 729
  • [18] Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas
    Clauditz, Till Sebastian
    Reiff, Maren
    Gravert, Linn
    Gnoss, Alexander
    Tsourlakis, Maria-Christina
    Muenscher, Adrian
    Sauter, Guido
    Bokemeyer, Carsten
    Knecht, Rainald
    Wilczak, Waldemar
    PATHOLOGY, 2011, 43 (05) : 459 - 464
  • [19] Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer
    Modi, Shanu
    Saura, Cristina
    Yamashita, Toshinari
    Park, Yeon Hee
    Kim, Sung-Bae
    Tamura, Kenji
    Andre, Fabrice
    Iwata, Hiroji
    Ito, Yoshinori
    Tsurutani, Junji
    Sohn, Joohyuk
    Denduluri, Neelima
    Perrin, Christophe
    Aogi, Kenjiro
    Tokunaga, Eriko
    Im, Seock-Ah
    Lee, Keun Seok
    Hurvitz, Sara A.
    Cortes, Javier
    Lee, Caleb
    Liu, Yali
    Zhang, Lin
    Shahidi, Javad
    Yver, Antoine
    Baselga, Jose
    Krop, Ian E.
    CANCER RESEARCH, 2021, 81 (04)
  • [20] Response of Human Epidermal Growth Factor Receptor 2-Expressing Prostate Cancer to Trastuzumab Deruxtecan
    Lap, Coen J.
    Rajendran, Rithika
    Martin, Jose Manuel
    Uppal, Manisha
    Escobar, Asha
    Heiraty, Angela M.
    Estephan, Fayez
    Hahn, Winnie
    Subrahmanyam, Ramesh
    Nava, Victor E.
    Jain, Maneesh
    ANNALS OF INTERNAL MEDICINE, 2024, 177 (12) : 1738 - 1741
12345